NCT07352306RecruitingPhase 4
Topical Diacerein in Psoriasis Vulgaris
The Efficacy of Topical Diacerein Cream in Patients With Psoriasis Vulgaris
Source: ClinicalTrials.gov · Last updated 22 Oct 2026
Brief summary (registry, in English)
The goal of this clinical trial is to evaluate the safety and effectiveness of topical diacerein in adults with psoriasis vulgaris. The primary objective of the study is to compare the proportion of participants who achieve a clinically meaningful improvement in disease severity between the topical diacerein group and the placebo group. Participants will: Be assigned to receive topical diacerein 1% or placebo twice daily for a treatment period of 2 months. Attend follow-up visits at Weeks 2, 4, 6, and 8. Undergo an additional evaluation one month after treatment cessation.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 11 Jan 2026
- Start date
- 11 Apr 2026
- Primary completion date
- 1 Feb 2027
- Lead sponsor
- Alaa Ashraf Muhammad Helal
- Diseases
- Psoriasis
- NCT number
- NCT07352306
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 60
- From 11 Apr 2026 to the primary completion date, 1 Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Documented hypersensitivity or idiosyncratic reaction to the investigational product or any excipients contained within the cream formulation.
- Intake of anti-psoriatic systemic therapy within the last 3 months, or topical treatments within the last 2 weeks.
Other
- Patients with pustular psoriasis.
- Pregnant and breast-feeding individuals.
- Patients with psoriatic arthritis.
Who the study is looking for
- Age ≥18 years old of both genders.
- Patients with mild chronic plaque psoriasis body surface area (BSA \< 10%) along with Psoriasis Area and Severity Index (PASI) score of \< 10, and/or Dermatology Life Quality Index (DLQI) score of \<10.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kasr Al-Ainy Psoriasis Unit Coordinator of this site? Confirm its status | Cairo | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.